Lords Mark Industries Limited (501261) — Announcement | 12 September 2026

Lords Mark Industries Limited presented its investor summit transcript on September 10, 2026, highlighting its dual focus on medical technology and renewable energy. The company, recently listed via reverse merger, showcased strong growth in IVD revenue (78% YoY) and renewable energy revenue (65% YoY), with a net debt/EBITDA ratio of 1.2x. It emphasized proprietary innovations like a low-cost sickle cell test, AI-powered dialysis machines, and plans to spin off renewable energy into a separate entity. The management outlined aggressive expansion plans including 50 dialysis centers by March 2027, US FDA approval targets, and global market entry via UK and Switzerland subsidiaries.